Our team has decades of experience on high quality monoclonal antibody development services. DIMA’s DimAb® development platform is a revolutionary technology platform for monoclonal antibody development. Different from hybridoma fusion platform, we can directly isolate IgG genes from B cells of immunized animals. At present, we have successfully completed a number of custom development projects with high satisfaction (Please see our customer testimonials).
Mouse is the best animal model system to study human diseases. Before clinical trial, mouse disease model is commonly used to simulate the pathogenesis of human diseases and test the drug responses. Till today, more than 90% of the therapeutic antibody drugs were developed from mouse or humanized mouse. There are well-established systems to humanize mouse monoclonal antibodies. Therefore, mouse is still the first choice when coming for a therapeutic antibody drug developmental program.
Although mouse hybridoma technology was developed several decades ago, it is still the major working horse people commonly using for monoclonal antibody development. However, there are limitations in the preparation of monoclonal antibodies by traditional hybridoma methods, such as low fusion efficiency of hybridoma, long preparation process, unstable hybridoma cells, etc. DIMA’s DimAb® technology platform for mouse monoclonal antibody development is a total revolution, which has a number of advantages.